BioSpace News Archive

TrialSpark, a tech-driven drug developer with its own portfolio of clinical stage drug assets, is rebranding to Formation Bio.

Sirnaomics Ltd. (the “Company”, Stock Code: 2257, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the successful completion of Cohort 1 in an ongoing Phase I clinical trial of STP122G, targeting Factor XI as a novel form of anticoagulation.

CG Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track Designation and Breakthrough Therapy Designation for cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ with or without Ta or T1 (papillary) tumors.

DiaCarta, Inc. announced that DiaCarta received US FDA 510 clearance for it’s over the counter at home iColon Fecal Occult Blood Test that enables early detection of blood in stool at home, which is clinically relevant in gastrointestinal disorders and colorectal cancer.